Bio-Rad Laboratories, Inc.
NYSE:BIO · New York Stock Exchange
-$0.65 today
Vol 0.21M · Avg 0.38M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:BIO · Revenue to Net Income
Key Ratios
Analysis
$2.6B of revenue converted into $168.8M of net income for the selected period. Gross margin is 51.9% and net margin is 2.8%, showing how much revenue survives after costs and taxes. EPS is $6.07, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6B +0.7% | $2.6B -3.9% | $2.7B -4.7% | $2.8B -4.1% | $2.9B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.2B +4.4% | $1.2B -4.6% | $1.2B +0.8% | $1.2B -3.9% | $1.3B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.3B -2.6% | $1.4B -3.4% | $1.4B -9.0% | $1.6B -4.3% | $1.6B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 52.0% -1.7pp | 53.7% +0.3pp | 53.4% -2.5pp | 55.9% -0.1pp | 56.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $256.9M -13.2% | $295.9M +19.6% | $247.4M -3.7% | $256.9M -1.4% | $260.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $819.9M +0.7% | $814.0M -3.3% | $841.7M +1.7% | $827.8M -5.6% | $877.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.1B -2.9% | $1.1B +1.9% | $1.1B +0.4% | $1.1B -4.7% | $1.1B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $205.4M +35.5% | $151.6M +3.9% | $145.9M -17.7% | $177.2M +28.8% | $137.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.2B +158.4% | -$2.1B -227.1% | -$654.8M +85.4% | -$4.5B -180.3% | $5.6B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 48.4% +131.8pp | -83.5% -58.9pp | -24.5% +135.7pp | -160.2% -351.4pp | 191.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $270.5M +0.6% | $269.0M -20.4% | $337.8M -30.0% | $482.6M -3.5% | $500.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 10.5% -0.0pp | 10.5% -2.2pp | 12.6% -4.6pp | 17.2% +0.1pp | 17.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $95.5M +16.5% | $82.0M -18.7% | $100.9M +74.0% | $58.0M +206.9% | $18.9M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $49.0M +0.2% | $48.9M -1.1% | $49.4M +29.7% | $38.1M +2357.4% | $1.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $725.0M +127.8% | -$2.6B -119.8% | -$1.2B +77.1% | -$5.2B -204.8% | $4.9B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $995.5M +142.5% | -$2.3B -175.6% | -$850.1M +81.9% | -$4.7B -186.3% | $5.4B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 38.5% +129.8pp | -91.3% -59.4pp | -31.8% +136.1pp | -167.9% -354.3pp | 186.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $235.6M +147.3% | -$498.3M -134.2% | -$212.8M +80.2% | -$1.1B -190.1% | $1.2B | $1.3B | -$1.6B | $745.2M |
| Net Income | $759.9M +141.2% | -$1.8B -189.4% | -$637.3M +82.4% | -$3.6B -185.3% | $4.3B | $4.9B | $4.8B | $4.7B |
| Net Margin | 29.4% +101.3pp | -71.9% -48.0pp | -23.9% +105.6pp | -129.5% -275.0pp | 145.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $28 +142.6% | -$65 -199.5% | -$22 +82.1% | -$122 -185.4% | $143 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $28 +142.6% | -$65 -199.5% | -$22 +82.1% | -$122 -186.5% | $141 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $27.3M -3.4% | $28.2M -3.4% | $29.2M -1.9% | $29.8M -0.2% | $29.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $27.3M -3.3% | $28.2M -3.4% | $29.2M -1.9% | $29.8M -1.4% | $30.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.62B
Align Technology, Inc.
NASDAQ:ALGN
$12.53B
Penumbra, Inc.
NYSE:PEN
$12.45B
Globus Medical, Inc.
NYSE:GMED
$10.25B
Masimo Corporation
NASDAQ:MASI
$9.42B
Henry Schein, Inc.
NASDAQ:HSIC
$9.10B
Charles River Laboratories International, Inc.
NYSE:CRL
$8.85B
AptarGroup, Inc.
NYSE:ATR
$7.60B
HealthEquity, Inc.
NASDAQ:HQY
$7.20B
Grifols, S.A.
NASDAQ:GRFS
$6.33B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BIO generate?
Bio-Rad Laboratories, Inc. (BIO) reported $2.58B of revenue in fiscal 2025.
Is BIO profitable?
Bio-Rad Laboratories, Inc. (BIO) reported $759.90M of net income, with a net margin of 29.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.